

## RESEARCH ARTICLE

# Association of a pace of aging epigenetic clock with rate of cognitive decline in the Framingham Heart Study Offspring Cohort

Micah J. Savin<sup>1</sup> | Haoyang Wang<sup>1,2</sup> | Heming Pei<sup>1,3</sup> | Allison E. Aiello<sup>1,3</sup> |  
 Stephanie Assuras<sup>4</sup> | Avshalom Caspi<sup>5,6,7,8</sup> | Terrie E. Moffitt<sup>5,6,7,8</sup> |  
 Peter A. Muenning<sup>9</sup> | Calen P. Ryan<sup>1</sup> | Baoyi Shi<sup>2</sup> | Yaakov Stern<sup>10,11,12</sup> |  
 Karen Sugden<sup>5,6</sup> | Linda Valeri<sup>2,3</sup> | Daniel W. Belsky<sup>1,3</sup>

<sup>1</sup>Robert N. Butler Columbia Aging Center, Mailman School of Public Health, Columbia University Irving Medical Center, New York, New York, USA

<sup>2</sup>Department of Biostatistics, MSPH, Columbia University Irving Medical Center, New York, New York, USA

<sup>3</sup>Department of Epidemiology, MSPH, Columbia University Irving Medical Center, New York, New York, USA

<sup>4</sup>Neuropsychology, Department of Neurology, Columbia University Irving Medical Center, New York, New York, USA

<sup>5</sup>Department of Psychology & Neuroscience, Trinity College of Arts & Sciences, Duke University, Durham, North Carolina, USA

<sup>6</sup>Department of Psychiatry and Behavioral Sciences, Duke University School of Medicine, Durham, USA

<sup>7</sup>PROMENTA, University of Oslo, Oslo, Norway, Problemveien 11, Oslo, Norway

<sup>8</sup>Social, Genetic & Developmental Psychiatry Centre, Institute of Psychiatry, Psychology, & Neuroscience, King's College London, London, United Kingdom, 16 De Crespigny Park, London, UK

<sup>9</sup>Health Policy and Management, Mailman School of Public Health, Columbia University Irving Medical Center, New York, New York, USA

<sup>10</sup>GH Sergievsky Center, Department of Neurology, Columbia University Irving Medical Center, New York, New York, USA

<sup>11</sup>Taub Institute, Department of Neurology, Columbia University Irving Medical Center, New York, New York, USA

<sup>12</sup>Cognitive Neuroscience Division, Department of Neurology, Columbia University Medical Center, New York, New York, USA

## Correspondence

Micah J. Savin, Robert N. Butler Columbia Aging Center, MSPH, Columbia University Irving Medical Center, New York, New York, USA.  
 Email: [ms6870@cumc.columbia.edu](mailto:ms6870@cumc.columbia.edu)

## Funding information

US National Institutes on Aging, Grant/Award Numbers: R01AG073402, R01AG073207; National Institute on Aging, Grant/Award Number: R01AG073402-0251

## Abstract

**INTRODUCTION:** The geroscience hypothesis proposes systemic biological aging is a root cause of cognitive decline.

**METHODS:** We analyzed Framingham Heart Study Offspring Cohort data ( $n = 2296$ ; 46% male; baseline age  $M = 62$ ,  $SD = 9$ , range = 25–101 y). We measured cognitive decline across two decades of neuropsychological-testing follow-up. We measured pace of aging using the DunedinPACE epigenetic clock. Analysis tested if participants with faster DunedinPACE values experienced more rapid cognitive decline compared with those with slower DunedinPACE values.

**RESULTS:** Participants with faster DunedinPACE had poorer cognitive functioning at baseline and experienced more rapid cognitive decline over follow-up. Results were robust to confounders and consistent across population strata. Findings were similar for the PhenoAge and GrimAge epigenetic clocks.

This is an open access article under the terms of the [Creative Commons Attribution-NonCommercial](https://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

© 2024 The Author(s). *Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring* published by Wiley Periodicals LLC on behalf of Alzheimer's Association.

**DISCUSSION:** Faster pace of aging is a risk factor for preclinical cognitive decline. Metrics of biological aging may inform risk stratification in clinical trials and prognosis in patient care.

**KEYWORDS**

aging, Alzheimer's disease and related dementias, biological aging, cognitive decline, DunedinPACE, epigenetic clocks

**Highlights**

Faster DunedinPACE is associated with preclinical cognitive aging.

Higher baseline cognition was protective of DunedinPACE-associated cognitive decline.

The DunedinPACE association with cognitive decline explained a fourth of dementia risk.

## 1 | INTRODUCTION

As we grow older, we experience a progressive loss of integrity and resilience capacity in our cells, tissues, and organs.<sup>1</sup> Within the emerging field of Geroscience, this process is referred to as “biological aging” and is thought to originate from an accumulation of molecular damage<sup>2</sup> that manifests as a series of cellular-level changes or “hallmarks of aging.”<sup>3</sup> These hallmarks of aging in turn are implicated in the etiology of many different chronic diseases, including Alzheimer's disease and related dementias (ADRD).<sup>4,5</sup>

One of the strongest phenotypic risk factors for ADRD is preclinical cognitive decline, a more rapid decline in cognitive abilities prior to meeting diagnostic criteria for mild cognitive impairment (MCI).<sup>6</sup> In observational cohort studies, the rate of preclinical cognitive decline varies, with some individuals maintaining healthy cognitive function for many years while others decline rapidly to ADRD onset.<sup>7,8</sup> Better understanding of the causes of this variation are needed to inform risk stratification in clinical trials and improve prognosis in clinical care.<sup>9</sup> Here, we test the geroscience-informed hypothesis that some individuals experience more rapid preclinical cognitive decline than others because they have a faster pace of biological aging.

We analyzed data from the Framingham Heart Study (FHS) Offspring Cohort. We modeled trajectories of cognitive decline from two decades of neuropsychological testing data. We measured pace of biological aging from DNA methylation data using the DunedinPACE epigenetic clock. We tested if participants with faster pace of aging exhibited accelerated cognitive decline. We evaluated robustness of results across specifications considering a range of confounders and effect modifiers, including smoking history, cell composition of blood samples used to derive DNA, presence of MCI at baseline, level of cognitive functioning at baseline, sex, and apolipoprotein E4 (APOE4) carrier status. Finally, we tested if pace of aging associations with cognitive decline reflected a process contributing to risk of dementia. We repeated analysis for two other proposed

metrics of biological aging, the PhenoAge and GrimAge epigenetic clocks.

## 2 | METHOD

### 2.1 | Participants

The FHS is an ongoing population-based cohort following three generations of families recruited, starting 1948, within the town of Framingham, Massachusetts, USA. We analyzed data from the second generation of participants, the Offspring Cohort. The Offspring Cohort ( $N = 7306$ ) was initiated in 1971, and participants have since been followed-up at nine examinations, approximately every 4–7 years. Our analysis focused on measurements of biological aging from DNA methylation (DNAm) data collected at the eighth follow-up visit and measurements of cognitive decline from neuropsychological test data collected beginning around the time of the seventh study visit and ongoing through 10 years after the ninth study visit (Figure S1).

### 2.2 | Biological aging

Given the basis of this prior evidence, we focus analyses on DunedinPACE as our primary independent variable. We include, for comparison, analysis of the two other epigenetic clocks with robust evidence for prediction of morbidity and mortality, PhenoAge<sup>10</sup> and GrimAge,<sup>11</sup> although prior evidence of their association with ADRD is inconsistent.<sup>12</sup> DNA methylation was measured from whole-blood DNA samples collected at the eighth study visit. Assays were performed with the Illumina 450K Array at the University of Minnesota and John Hopkins University (dbGaP phs000724.v9.p13). Array data from both sites were pooled and processed from raw IDAT files by the Geroscience Computational Core of the Robert N. Butler Columbia

Aging Center. After quality control, data were available for  $n = 2296$  participants. Details of the preprocessing and quality control steps employed are reported in the Supplemental Methods.

### 2.2.1 | DunedinPACE

The DunedinPACE epigenetic clock is a measure of the pace of biological aging.<sup>13</sup> It was developed from analysis of longitudinal change in 19 biomarkers of the integrity of the cardiovascular, metabolic, renal, hepatic, immune, dental, and pulmonary systems over a 20-year follow-up period in the Dunedin Study birth cohort. The DunedinPACE algorithm was developed by first modeling change over the 20 years of follow-up to create a composite Pace of Aging phenotype.<sup>14,15,16</sup> Next, Pace of Aging was modeled from whole-blood DNA methylation measured at the age-45 follow-up to derive the DunedinPACE algorithm.<sup>13</sup> DunedinPACE has an expected value of 1 in midlife adults, corresponding to a rate of 1 year of biological aging per 12 months of calendar time. Values  $> 1$  indicate a faster pace of aging (e.g., a value of 1.25 would indicate a pace of aging 25% faster than the norm for midlife adults); values  $< 1$  indicate a slower pace of aging (e.g., a value of 0.75 would indicate a pace of aging 25% slower than the norm for midlife adults). We computed DunedinPACE in Framingham Heart Study participants using the R package available from GitHub (<https://github.com/danbelsky/DunedinPACE>). For analysis, DunedinPACE values were scaled to have  $M = 0$  and  $SD = 1$ .

### 2.2.2 | Other epigenetic clocks

In contrast to DunedinPACE, which measures pace of aging, GrimAge and PhenoAge are static measures of biological age,<sup>10,11</sup> that is, DunedinPACE was designed as a speedometer, PhenoAge and GrimAge were designed as odometers, estimates of how much aging has occurred by the time of measurement.<sup>17</sup> We analyzed versions of the PhenoAge and GrimAge clocks calculated from DNA methylation principal components ("PC Clocks"), which have better technical reliability than the original versions of these clocks.<sup>18</sup> PC Clocks were calculated using the R package available from GitHub (<https://github.com/MorganLevineLab/PC-Clocks>). We regressed clock-age values on participants' chronological ages and computed residual values interpretable as how many more (or fewer) years of biological aging a person has experienced compared with the expectation based on their chronological age. For analysis, PhenoAge and GrimAge residuals were scaled to have  $M = 0$  and  $SD = 1$ .

### 2.2.3 | Immune cell composition

Blood DNAm derives from white blood cells, with the precise mixture of different types varying between individuals. To account for the possibility that this heterogeneity could confound associations between epigenetic clocks and cognitive decline, we com-

## RESEARCH IN CONTEXT

- 1. Systematic review:** The authors reviewed the literature using PubMed and Google Scholar. Variability in rates of cognitive decline with aging is well documented. But whether this variation reflects differences in the pace of biological aging is unknown. The relevant citations are appropriately cited.
- 2. Interpretation:** Our findings suggest that faster pace of biological aging is associated with more rapid cognitive decline. Interventions to slow the pace of aging could contribute to protection of cognition in aging.
- 3. Future directions:** The manuscript describes the application of pace of aging measures to understand risk for cognitive decline and encourages the conduct of additional studies in representative and diverse samples disproportionately at-risk. Examples include further understanding the validity and utility of DNA methylation biomarkers of biological aging as risk assessment tools for Alzheimer's disease and related dementias among ethnically and racially diverse United States (US) adults.

puted a set of control variables from the DNAm data to estimate the relative abundances of different cell types.<sup>19</sup> We computed values using the *estimateCellCounts2* function from the *FlowSorted.BloodExtended.EPIC* R package developed by Salas et al. using the *preprocessNoob* setting on both these data and the cell reference dataset.<sup>20</sup> The package estimates relative abundances of 12 different types of immune cells (basophils, B naïve, B memory, CD4T naïve, CD4T memory, CD8T naïve, CD8T memory, eosinophils, monocytes, neutrophils, T regulatory cells, and natural killer cells).

## 2.3 | Neuropsychological examination

All participants underwent annual standardized neuropsychological examinations beginning 19 to 47 years from study baseline and extending over 24 years of follow-up. We analyzed data from the FHS's original neuropsychological battery.<sup>21</sup> The tests in this battery were organized into eight cognitive domains according to factor analysis conducted by the FHS Investigators<sup>21</sup> (Table S1). To integrate scores on these tests into a measure of global cognitive functioning, we followed the approach described by Downer et al.<sup>22</sup> First, we converted scores on each cognitive test to T-scores ( $M = 50$ ,  $SD = 10$ ) based on their distributions at baseline among individuals who remained free of dementia, Alzheimer's disease, and cerebrovascular disease through the end of follow-up ( $N = 5010$ , 44% male, age:  $M = 60$ ,  $SD = 16$ ).<sup>23</sup> Next, we averaged the test-specific scores to compute our dependent variable for the main analysis, a measure of global cognitive functioning as defined by the Framingham Investigators.<sup>21,30</sup>

Following established practices, global cognitive functioning scores were computed for participants with non-missing data on  $\geq 70\%$  of neuropsychological tests.<sup>24</sup>

### 2.3.1 | Cognitive status criteria

MCI was defined following the FHS Investigators' practice as impaired performance by  $> 1$  SD on two or more cognitive tests in any domain.<sup>25,26</sup> Dementia status, subtype, and date of onset was defined by the FHS dementia review panel, which included serial assessments up to the time of death by staff neurologists and neuropsychologists, telephone interviews with caregivers, medical records, neuroimaging studies, and when available, autopsies.<sup>23,27</sup>

### 2.3.2 | Cognitive reserve

A prominent hypothesis in neuropsychology is that individuals vary in their cognitive resilience to neuropathology.<sup>28</sup> This phenomenon, referred to as cognitive reserve, could play a role as an effect-modifier in our analysis of pace of aging and cognitive decline. To explore this possibility, we tested baseline cognitive functioning as a modifier of associations between DunedinPACE and cognitive decline. For analysis of cognitive reserve, we computed average values across global cognition T-scores from neuropsychological assessments prior to DNAm baseline and dichotomized these average values at the healthy-population mean value of 50.

## 2.4 | Educational attainment

Education was measured continuously as defined by completed years of schooling. For analysis, years of schooling was centered at 12 y and scaled in 4 y units.

## 2.5 | Obesity

Obesity was measured from anthropometric assessments of height and weight. We computed body mass index (BMI) as weight in kilograms divided by height in meters squared. We coded these values as lean (BMI = 18–25), overweight (BMI = 25–30), and obese (BMI > 30).

## 2.6 | Smoking history

Smoking is known to affect blood DNA methylation and is also linked with cognitive decline.<sup>29,30</sup> To address potential confounding by smoking history, we created a composite index to summarize participants' smoking history across the eight waves of follow-up prior to DNA methylation measurement. At each measurement wave, participants

reported their smoking status as never, former, or current. We coded these responses as 0, 1, and 2, respectively, and averaged values across waves to form the final index.

## 2.7 | APOE4

APOE4 status is a well-known risk factor for cognitive decline.<sup>31</sup> We assessed APOE4 as an effect modifier. APOE4 allele carrier status was coded dichotomously (one or more APOE4 alleles versus no APOE4 allele).

## 2.8 | Statistical analysis

Analysis included  $n = 2296$  participants with DNA methylation data passing quality controls and measured global cognition at one or more assessments. We analyzed changes in global cognitive functioning using mixed-effects growth models implemented using the *lme4* package in the R software.<sup>32,33</sup> Our base model tested for change in cognition over time from DNAm and included covariates for age at baseline (linear and quadratic terms scaled in 10-yearly units and centered at 65 years), sex, a set of time-varying terms for follow-up time from DNAm (linear and quadratic terms scaled in 5-year units) and the interaction of age at baseline with follow-up time (linear and quadratic; Table S2).

### 2.8.1 | Testing pace of aging as a risk factor for cognitive decline

To test our hypothesis that faster pace of aging would predict more rapid cognitive decline, we added a term to the model for DunedinPACE and a product term modeling interaction between DunedinPACE and linear and quadratic follow-up time. The product terms tested association of DunedinPACE with rate of cognitive decline.

### 2.8.2 | Confounder adjustment

To address confounding by factors known to influence both cognitive decline and DNA methylation via pathways other than pace of aging, we repeated analysis adding covariates to the model for educational attainment, obesity, smoking history, and leukocyte composition of blood samples used to derive DNA.

### 2.8.3 | Restriction of the analysis sample to participants who were cognitively intact at baseline

To evaluate sensitivity of results to patterns of decline among individuals already showing signs of impairment, we repeated the analysis excluding individuals who manifested MCI prior to DNAm measurement.

## 2.8.4 | Effect modification

We conducted effect-modification analysis to evaluate contributions of cognitive-reserve processes, sex, and APOE4 carrier status to associations of pace of aging with cognitive decline. We tested effect modification by including main-effect terms for effect-modifiers along with product terms testing their interaction with follow-up time, DunedinPACE, and the Time\*DunedinPACE term.

## 2.8.5 | Mediation

To test if more rapid cognitive decline mediated excess risk of dementia in individuals with a faster pace of aging, we conducted formal mediation analysis using the survival analysis function within the CMAverse software (<https://bs1125.github.io/CMAverse/>).

## 2.8.6 | Other clocks

We repeated analyses replacing DunedinPACE terms in our models with terms for the age-residuals of the PhenoAge and GrimAge epigenetic clocks.

Analysis code will be available on GitHub upon acceptance.

## 3 | RESULTS

We analyzed data for 2296 non-Hispanic White adults in the FHS Offspring Cohort followed for up to 23 years ( $M$  age = 62,  $SD$  = 9; 55% women;  $M$  global cognition T-score = 51,  $SD$  = 5,  $Mdn$  visits = 4,  $IQR$  = 2–12). At DNAm baseline, 23% of this sample met criteria for mild cognitive impairment; over follow-up, 12% were diagnosed with dementia, including Alzheimer's disease. A comparison of the FHS Offspring sample analyzed here with the larger cohort is reported in Table 1.

Participants' global cognition scores declined over follow-up (per 5 years of follow-up,  $B$  = -1.54, 95%  $CI$  = [-1.66, -1.42]). Participants who were older at baseline experienced more rapid decline compared with those who were younger (age-by-time interaction  $B$  = -4.45 [-4.38, -4.53],  $p$  < 0.001).

### 3.1 | Adults with faster pace of aging experienced more rapid cognitive decline

To test the hypothesis that participants who were experiencing a faster pace of biological aging would also exhibit more rapid cognitive decline, we tested associations of participants' pace of aging with change over time in their global cognition scores. Participants with a faster pace of aging tended to have worse average cognitive performance (DunedinPACE  $B$  = -0.92 [-1.16, -0.68],  $p$  < 0.001) and more rapid cognitive decline over follow-up (DunedinPACE  $B$  = -0.21 [-0.32, -0.09],  $p$  < 0.001).

**TABLE 1** The table reports characteristics of the Framingham Heart Study (FHS) Offspring Cohort and of the participants in that cohort included in our analysis.

| Parameter                  | Offspring Cohort<br>N = 7306 | Analytic Sample<br>n = 2296 |
|----------------------------|------------------------------|-----------------------------|
|                            | $M(SD)$ / %                  |                             |
| Chronological age (years)  | 61 (14)                      | 62 (9)                      |
| % Male                     | 44%                          | 45%                         |
| Education (years)          | 15 (3)                       | 15 (2)                      |
| Global cognition (T-score) | 52 (5)                       | 51 (5)                      |
| % Dementia                 | 12%                          | 8%                          |
| % Alzheimer's disease      | 9%                           | 5%                          |
| % Cerebrovascular disease  | 2%                           | 2%                          |
| % Dead                     | 33%                          | 25%                         |

*Note:* The analytic sample includes participants with DNA methylation data and complete data from at least one neuropsychological exam. Complete neuropsychological exam data were defined as > 70% non-missing data across tests. Rows 1 and 2 reports demographic characteristics at study baseline (available for all participants). Row 3 reports data on educational attainment (available for 77% of the Offspring Cohort and 99% of the Analytic Sample). Rows 5–8 reports data on incidence of dementia, Alzheimer's disease, cerebrovascular disease, and mortality through the end of follow-up (available for 79% of the Offspring Cohort and 99% of the Analytic Sample).

Results were similar for the PhenoAge and GrimAge epigenetic clocks. Complete results for all clocks are shown in Table 2. Trajectories of cognitive aging for participants with slower and faster pace of aging/ older and younger biological age are illustrated in Figure 1.


We evaluated potential confounding of associations by educational attainment, obesity, smoking history, and leukocyte composition of blood samples by adding covariates for these variables to our regression model. Results were similar to the primary model (Table 2, Table S2).

Finally, we repeated analysis excluding individuals who manifested MCI at DNAm baseline. Results were similar to our primary model (Table 2).

### 3.2 | Exploration of effect modification by ADRD risk factors

We conducted exploratory analyses to evaluate sensitivity of associations between pace of aging and cognitive decline to modification by ADRD risk factors: cognitive reserve, sex, and APOE4 carrier status.<sup>28,31,34,35,36,37</sup> Cognitive reserve was not directly observed in our study. To conduct the sensitivity analysis, we grouped participants according to level of cognitive functioning at baseline (above/below a T-score of 50) to serve as a proxy of premorbid level of functioning. Participants with better baseline cognitive functioning were somewhat protected from risk associated with a faster pace of aging; being in the high-function group was associated with a reduction in the association of DunedinPACE with rate of cognitive decline by 36% (interaction





**FIGURE 1** Predicted cognitive change over follow-up in Framingham Heart Study Offspring Cohort members with faster and slower pace of aging/older and younger biological age. Data are plotted for analysis of three epigenetic clocks ( $n = 2296$ ). The top row shows analysis of the DunedinPACE epigenetic clock. The middle row shows analysis of the PhenoAge epigenetic clock. The bottom row shows analysis of the GrimAge epigenetic clock. Within each row, there are two graphs. The left-side graphs plot predicted trajectories of cognitive change over time for participants aged 65 at the time of DNAm collection. The Y axis shows cognitive functioning. The X axis shows follow-up time, centered at the time of DNAm collection (i.e., time is coded as zero at Study visit 8, when DNAm was collected). The dashed slope plots change for those with slow pace of aging/younger biological age (1 standard deviation [SD] below the mean). The solid slope plots change for those with fast pace of aging/older biological age (1 SD above the mean). The graphs show that participants with faster pace of aging/older biological age had poorer average cognitive functioning at baseline and experienced more rapid cognitive decline over follow-up compared with those with slower pace of aging/younger biological age. The right-side graphs plot differences in cognitive functioning per epigenetic-clock SD over follow-up time. The graphs show that differences in cognitive functioning between those with faster/slower pace of aging and older/younger biological age increase with follow-up time.

**TABLE 2** Epigenetic clock associations with cognitive functioning at baseline and cognitive decline over follow-up.

|  | DunedinPACE |              |        | PhenoAge |              |        | GrimAge |              |        |
|--|-------------|--------------|--------|----------|--------------|--------|---------|--------------|--------|
|  | B           | CI           | p      | B        | CI           | p      | B       | CI           | p      |
| <i>Base Model</i>  |             |              |        |          |              |        |         |              |        |
| Intercept  | -0.92       | -1.16, -0.68 | <0.001 | -0.66    | -0.89, -0.43 | <0.001 | -0.92   | -1.16, -0.68 | <0.001 |
| Linear Slope   | -0.21       | -0.32, -0.09 | <0.001 | -0.24    | -0.35, -0.12 | <0.001 | -0.20   | -0.31, -0.09 | <0.001 |
| Quadratic Slope  | 0.03        | -0.03, 0.09  | 0.294  | 0.01     | -0.05, 0.07  | 0.782  | 0.01    | -0.05, 0.07  | 0.750  |
| <i>Adjusted for smoking history and DNAm-estimated leukocyte composition of DNA sample</i> |             |              |        |          |              |        |         |              |        |
| Intercept  | -0.79       | -1.06, -0.53 | <0.001 | -0.61    | -0.91, -0.31 | <0.001 | -0.86   | -1.17, -0.54 | <0.001 |
| Linear Slope   | -0.21       | -0.32, -0.09 | <0.001 | -0.24    | -0.35, -0.12 | <0.001 | -0.20   | -0.31, -0.09 | <0.001 |
| Quadratic Slope  | 0.04        | -0.03, 0.10  | 0.258  | 0.01     | -0.05, 0.07  | 0.742  | 0.01    | -0.05, 0.07  | 0.725  |
| <i>Excluding participants with mild cognitive impairment at DNAm baseline</i>              |             |              |        |          |              |        |         |              |        |
| Intercept  | -0.76       | -0.99, -0.53 | <0.001 | -0.58    | -0.81, -0.35 | <0.001 | -0.79   | -1.02, -0.56 | <0.001 |
| Linear Slope   | -0.26       | -0.38, -0.13 | <0.001 | -0.23    | -0.36, -0.11 | <0.001 | -0.24   | -0.36, -0.11 | <0.001 |
| Quadratic Slope  | 0.05        | -0.01, 0.12  | 0.093  | 0.02     | -0.04, 0.08  | 0.534  | 0.02    | -0.04, 0.08  | 0.534  |

Note: The table shows results from mixed-effects regression analysis of changes in global cognition over up to 23 years of follow-up in the Framingham Heart Study Offspring Cohort ( $n = 2296$ ). Results are reported for three different epigenetic clocks (left column shows results for DunedinPACE; center column shows results for PhenoAge; right column shows results for GrimAge). Each set of results shows coefficient estimates, 95% CIs, and  $p$ -values for associations of epigenetic clocks with level of cognitive functioning at baseline (Intercept), linear slope of decline (Linear Slope), and quadratic slope of decline (Quadratic Slope). Results are reported for three sets of models. The base model included covariate adjustment for sex, age at baseline (quadratic), and associations of age at baseline with linear and quadratic slopes of cognitive decline. The second model added covariate adjustment for smoking history and DNA-estimated leukocyte composition. The third model excluded participants with mild cognitive impairment at DNA methylation baseline ( $n = 528$ ). Follow-up time was denominated in 5-year units. Coefficient estimates are denominated in global cognition T-score units per 1 standard deviation of the epigenetic clocks.

$b = 0.42$ , [0.19, 0.65],  $p < 0.001$ ). However, this effect modification was not observed for the PhenoAge and GrimAge clocks (interaction  $Bs < 0.12$ ,  $p$ -values  $> 0.3$ ). Trajectories of estimated marginal effects by year of follow-up for participants with slower and faster pace of aging and low and high cognitive reserve are graphed in Figure 2. Complete results for all clocks are reported in Table S3 and graphed in Figure 2. Associations of pace of aging with rate of cognitive decline were similar for men and women (interaction  $Bs \leftarrow 0.12$ ,  $p$ -values  $> 0.3$ ; Table S3) and for carriers and non-carriers of APOE4 (interaction  $Bs < 0.18$ ,  $p$ -values  $> 0.132$ ; Table S3).

### 3.3 | Evaluation of dementia risk mediation

We previously reported that Framingham participants with faster pace of aging were at increased risk of developing dementia.<sup>38</sup> To integrate our current findings with this observation, we conducted mediation analysis. For mediation analysis, we restricted neuropsychological testing follow-up to the first three assessments following DNAm collection to avoid overlap with dementia diagnosis. Follow-up for mediation analysis included up to 14 years following DNAm collection. Over this period, 518 participants were diagnosed with dementia (mean follow-up to diagnosis = 9.34 years (SD = 3.54)).


Participants with faster DunedinPACE values had increased risk of dementia over follow-up (Total Effect HR = HR = 1.62 [1.29, 2.03],  $p < 0.001$ ). Roughly 24% of this risk was mediated through accelerated cognitive decline over the first three assessments following DNAm collection (Indirect Effect HR = 1.10 [1.05, 1.14],  $p < 0.001$ ). Full results

are reported in Table S4. Including covariate adjustment for level of cognitive functioning at baseline attenuated effect-sizes, but associations remained statistically different from zero (Total Effect HR = 1.42 [1.21, 1.81],  $p = 0.003$ ; Indirect Effect HR = 1.05 [1.01, 1.09],  $p = 0.011$ ). Results were similar for PhenoAge and GrimAge, although associations of these clocks with dementia risk were smaller in magnitude (Total Effect HRs  $< 1.21$ ) and not statistically different from zero ( $p > 0.06$ ). Complete results are reported in Table S4.

A full comparison of clock effect sizes across models is reported in Figure S2.

## 4 | DISCUSSION

We analyzed longitudinal neuropsychological testing data collected over two decades of follow-up in the FHS Offspring Cohort to test if older adults with faster pace of biological aging experienced accelerated cognitive aging. We previously found that a faster pace of aging was associated with declines in IQ from childhood to midlife, signs of early brain aging, and earlier onset of dementia among older adults.<sup>13–15,38</sup> However, no data yet address whether faster pace of aging is associated with preclinical cognitive decline among older adults. In this study, we found that older adults with faster pace of aging as measured by the DunedinPACE epigenetic clock showed poorer cognitive functioning at baseline and experienced more rapid decline over follow-up. Our findings supported the robustness of this result across specifications considering a range of confounders, effect modifiers, and mediation analyses.



**FIGURE 2** Associations of epigenetic clocks with cognitive change over follow-up in Framingham Heart Study Offspring Cohort members with high and low baseline cognitive functioning. The figure plots differences in cognitive functioning per epigenetic-clock standard deviation (SD) over follow-up time for participants grouped by baseline cognitive functioning ( $n = 2296$ ). Data are plotted for analysis of three epigenetic clocks. The left graph shows analysis of the DunedinPACE epigenetic clock. The middle graph shows analysis of the PhenoAge epigenetic clock. The right graph shows analysis of the GrimAge epigenetic clock. Within each graph, the dashed slope shows the trend for participants with high baseline cognitive functioning ( $T > 50$ ). The solid slope shows the trend for participants with low baseline cognitive functioning ( $T < 50$ ). DunedinPACE analysis shows that a faster pace of aging is associated with more rapid cognitive decline for those with low cognitive functioning at baseline, but this association is attenuated for participants with higher cognitive functioning at baseline. In contrast, in PhenoAge and GrimAge analysis, older biological age was associated with the same degree of decline regardless of baseline cognitive functioning.

Our findings have implications for theory and research. With respect to theory, there are three implications. First, the extent to which cognitive decline reflects brain-specific or systemic processes is not fully understood. In previous studies, midlife and older adults with faster pace of aging exhibited brain characteristics linked with neuropathologies of aging, including cortical thinning and hippocampal atrophy,<sup>39,40</sup> suggesting connections between systemic aging and aging of the brain. This study complements those findings with evidence of corresponding decline in cognitive functioning. Together, our findings build the case that systemic biological aging contributes to the aging of the brain. The critical next steps are studies that can establish the temporal ordering of accelerated pace of aging, brain changes, and cognitive decline.

Second, whether biological aging contributes to dementia risk through an acceleration of preclinical cognitive decline versus increased risk of major neuropathologic events is unknown. We found that older adults with faster DunedinPACE experienced more rapid preclinical cognitive decline. Moreover, accelerated cognitive decline mediated roughly a quarter of the DunedinPACE association with dementia. Collectively, these results suggest a faster pace of biological aging contributes to accelerated preclinical cognitive decline and associated dementia risk. However, they also suggest that trajectories of preclinical decline are only one of multiple paths linking accelerated biological aging with dementia. Future studies

should investigate the role of strokes and other neuropathological insults in linking faster pace of aging with increased dementia risk.

Third, sources of resilience to a faster pace of biological aging are unknown. In neuropsychology, the cognitive reserve hypothesis proposes that features of the brain that support cognitive functions buffer against cognitive decline in the face of accumulating neuropathology.<sup>28,41</sup> A common approach to testing this hypothesis is to test effect modification of cognitive decline by baseline levels of cognition. In the FHS, we found that a faster pace of aging was less deleterious among older adults who had higher cognitive functioning at baseline compared with adults who had poorer cognitive functioning at baseline. This result suggests pace of aging may relate to features of the brain promoting cognitive resilience to neuropathology. Studies are needed to identify the ways in which specific brain features may interact with pace of aging to affect trajectories of cognitive decline.

With respect to research, our findings contribute new evidence that an accelerated pace of aging is a harbinger of future dementia risk. Ultimately, tools like DunedinPACE could prove useful to clinicians treating cognitively intact older adults with subjective complaints, uncertain AD/DRD biomarker classifications, and ambiguous trajectories of cognitive decline. Finally, the connections between pace of aging and cognitive decline identified in our results suggest that interventions that slow pace of aging may also contribute to neuroprotection. As



further evidence accumulates, DunedinPACE and related tools could provide near-term outcome measures for intervention studies seeking to modify life course accumulation of risk for AD/ADRD.<sup>42,43</sup>

We acknowledge limitations. There is no gold standard measure of biological aging.<sup>1</sup> We focused on DunedinPACE based on three lines of evidence. First, DunedinPACE is predictive of diverse aging-related outcomes, including disease, disability, and mortality.<sup>13</sup> Second, DunedinPACE is associated with social determinants of healthy aging in young, midlife, and older adults.<sup>13,44,45</sup> Third, DunedinPACE is modified by calorie restriction, an intervention that affects core biological processes of aging in animal experiments.<sup>46</sup> Generally, we saw similar effect sizes across DNAm epigenetic clocks, supporting the robustness of the findings. Our study relied on an observational design. Results do not establish causality of associations between DunedinPACE and cognitive decline. However, our longitudinal design does help establish temporal ordering of faster pace of aging and subsequent cognitive decline. Our data do not establish which domains of cognitive functioning are most affected by pace of aging. The FHS neuropsychological battery includes only a single test in some domains and multiple tests in others; comparative analyses would be confounded by measurement artifacts.<sup>24</sup> The FHS Offspring Cohort we analyzed does not represent the US population. The FHS recruited its participants in a single city in New England. The Offspring Cohort is overwhelmingly Non-Hispanic White. Replication in more diverse cohorts, especially those representing populations at higher risk for AD/ADRD, are essential to generalizing results from this study.

## ACKNOWLEDGMENTS

D.W.B. is a fellow of the CIFAR CBD Network. This project was supported by US National Institutes on Aging grants R01AG073402, R01AG073207. M.J.S. is supported by a Diversity Supplement from the National Institute on Aging R01AG073402-0251. D.W.B. is a fellow of the CIFAR CBD Network.

## CONFLICT OF INTEREST STATEMENT

A.C., T.E.M., K.S., and D.W.B. are inventors of the Duke University and University of Otago Invention DunedinPACE, which is licensed to TruDiagnostic. There are no other conflicts of interest.

## CONSENT STATEMENT

The study protocol was approved by the institutional Review Board for Human Research at Boston University Medical Center, and all participants provided written informed consent. Data for the Framingham Offspring Study were obtained from dbGaP (phs000007.v33.p14).

## REFERENCES

- Ferrucci L, Gonzalez-Freire M, Fabbri E, et al. Measuring biological aging in humans: A quest. *Aging Cell*. 2020;19(2):e13080. doi:10.1111/ace.13080
- Gladyshev VN, Kritchevsky SB, Clarke SG, et al. Molecular damage in aging. *Nat Aging*. 2021;1(12):1096-1106. doi:10.1038/s43587-021-00150-3
- López-Otín C, Blasco MA, Partridge L, Serrano M, Kroemer G. Hallmarks of aging: an expanding universe. *Cell*. 2023;186(2):243-278. doi:10.1016/j.cell.2022.11.001
- Gonzales MM, Garbarino VR, Pollet E, et al. Biological aging processes underlying cognitive decline and neurodegenerative disease. *J Clin Invest*. 2023;132(10):e158453. doi:10.1172/JCI158453
- Kaeberlein M, Galvan V. Rapamycin and Alzheimer's disease: time for a clinical trial? *Sci Transl Med*. 2019;11(476):eaar4289. doi:10.1126/scitranslmed.aar4289
- Payton NM, Marseglia A, Grande G, et al. Trajectories of cognitive decline and dementia development: a 12-year longitudinal study. *Alzheimers Dement*. 2023;19(3):857-867. doi:10.1002/alz.12704
- Salthouse TA. Trajectories of normal cognitive aging. *Psychol Aging*. 2019;34(1):17-24. doi:10.1037/pag0000288
- Hartshorne JK, Germine LT. The asynchronous rise and fall of different cognitive abilities across the life span. *Psychol Sci*. 2015;26(4):433-443. doi:10.1177/0956797614567339. When does cognitive functioning peak?
- Rodrigues EA, Christie GJ, Cosco T, Farzan F, Sixsmith A, Moreno S. A subtype perspective on cognitive trajectories in healthy aging. *Brain Sci*. 2024;14(4):351. doi:10.3390/brainsci14040351
- Levine ME, Lu AT, Quach A, et al. An epigenetic biomarker of aging for lifespan and healthspan. *Aging*. 2018;10(4):573-591. doi:10.18632/aging.101414
- Lu AT, Quach A, Wilson JG, et al. DNA methylation GrimAge strongly predicts lifespan and healthspan. *Aging*. 2019;11(2):303-327. doi:10.18632/aging.101684
- Zhou A, Wu Z, Zaw Phyto AZ, Torres D, Vishwanath S, Ryan J. Epigenetic aging as a biomarker of dementia and related outcomes: a systematic review. *Epigenomics*. 2022;14(18):1125-1138. doi:10.2217/epi-2022-0209
- Belsky DW, Caspi A, Corcoran DL, et al. DunedinPACE, a DNA methylation biomarker of the pace of aging. *eLife*. 2022;11:e73420. doi:10.7554/eLife.73420
- Belsky DW, Caspi A, Houts R, et al. Quantification of biological aging in young adults. *Proc Natl Acad Sci U S A*. 2015;112(30):E4104-4110. doi:10.1073/pnas.1506264112
- Elliott ML, Belsky DW, Knodt AR, et al. Brain-age in midlife is associated with accelerated biological aging and cognitive decline in a longitudinal birth cohort. *Mol Psychiatry*. 2021;26(8):3829-3838. doi:10.1038/s41380-019-0626-7
- Elliott ML, Caspi A, Houts RM, et al. Disparities in the pace of biological aging among midlife adults of the same chronological age have implications for future frailty risk and policy. *Nat Aging*. 2021;1(3):295-308. doi:10.1038/s43587-021-00044-4
- Ryan CP. Epigenetic clocks': theory and applications in human biology. *Am J Hum Biol*. 2021;33(3). doi:10.1002/ajhb.23488
- Higgins-Chen AT, Thrush KL, Wang Y, et al. A computational solution for bolstering reliability of epigenetic clocks: implications for clinical trials and longitudinal tracking. *Nat Aging*. 2022;2(7):644-661. doi:10.1038/s43587-022-00248-2
- Bell CG, Lowe R, Adams PD, et al. DNA methylation aging clocks: challenges and recommendations. *Genome Biol*. 2019;20(1):249. doi:10.1186/s13059-019-1824-y
- Salas LA, Zhang Z, Koestler DC, et al. Enhanced cell deconvolution of peripheral blood using DNA methylation for high-resolution immune profiling. *Nat Commun*. 2022;13:761. doi:10.1038/s41467-021-27864-7
- Au R, Seshadri S, Wolf PA, et al. New norms for a new generation: cognitive performance in the framingham offspring cohort. *Exp Aging Res*. 2004;30(4):333-358. doi:10.1080/03610730490484380
- Downer B, Fardo DW, Schmitt FA. A summary score for the Framingham Heart Study Neuropsychological Battery. *J Aging Health*. 2015;27(7):1199-1222. doi:10.1177/0898264315577590
- Satizabal CL, Beiser AS, Chouraki V, Chêne G, Dufouil C, Seshadri S. Incidence of dementia over three decades in the Framingham Heart Study. *N Engl J Med*. 2016;374(6):523-532. doi:10.1056/NEJMoa1504327

24. Heaton RK, Marcotte TD. Clinical neuropsychological tests and assessment techniques. *Handbook of Neuropsychology: Sect. 2nd Ed.* Elsevier Science Publishers B.V.; 2000:27-52. Handbook of neuropsychology.
25. Wong CG, Thomas KR, Edmonds EC, et al. Neuropsychological criteria for mild cognitive impairment in the Framingham Heart Study's Old-Old. *Dement Geriatr Cogn Disord.* 2018;46(5-6):253-265. doi:10.1159/000493541
26. Bondi MW, Edmonds EC, Jak AJ, et al. Neuropsychological criteria for mild cognitive impairment improves diagnostic precision, biomarker associations, and progression rates. *J Alzheimers Dis JAD.* 2014;42(1):275-289. doi:10.3233/JAD-140276
27. Au R, Seshadri S, Knox K, et al. The Framingham Brain Donation Program: neuropathology along the cognitive continuum. *Curr Alzheimer Res.* 2012;9(6):673-686. doi:10.2174/156720512801322609
28. Stern Y. How can cognitive reserve promote cognitive and neurobehavioral health?. *Arch Clin Neuropsychol.* 2021;36(7):1291-1295. doi:10.1093/arclin/acab049
29. Joeannes R, Just AC, Marioni RE, et al. Epigenetic signatures of cigarette smoking. *Circ Cardiovasc Genet.* 2016;9(5):436-447. doi:10.1161/CIRCGENETICS.116.001506
30. Sabia S, Elbaz A, Dugravot A, et al. Impact of smoking on cognitive decline in early old age: the whitehall ii cohort study. *Arch Gen Psychiatry.* 2012;69(6):627-635. doi:10.1001/archgenpsychiatry.2011.2016
31. Gharbi-Meliani A, Dugravot A, Sabia S, et al. The association of APOE  $\epsilon$ 4 with cognitive function over the adult life course and incidence of dementia: 20 years follow-up of the Whitehall II study. *Alzheimers Res Ther.* 2021;13(1):5. doi:10.1186/s13195-020-00740-0
32. Ghisletta P, Mason F, von Oertzen T, Hertzog C, Nilsson LG, Lindenberger U. On the use of growth models to study normal cognitive aging. *Int J Behav Dev.* 2020;44(1):88-96. doi:10.1177/0165025419851576
33. Bates D, Mächler M, Bolker B, Walker S. Fitting linear mixed-effects models using lme4. *J Stat Softw.* 2015;67:1-48. doi:10.18637/jss.v067.i01
34. Stites SD, Cao H, James R, Harkins K, Coykendall C, Flatt JD. A systematic review of measures of gender and biological sex: exploring candidates for Alzheimer's disease and related dementias (AD/ADRD) research. *Alzheimers Dement Diagn Assess Dis Monit.* 2023;15(1):e12359. doi:10.1002/dad2.12359
35. Steward A, Biel D, Dewenter A, et al. ApoE4 and connectivity-mediated spreading of tau pathology at lower amyloid levels. *JAMA Neurol.* 2023;80(12):1295-1306. doi:10.1001/jamaneurol.2023.4038
36. Graf GH, Aiello AE, Caspi A, et al. Educational Mobility, the Pace of Biological Aging, and Lifespan in the Framingham Heart Study. Published online November 5, 2023:2023.11.04.23298091. doi:10.1101/2023.11.04.23298091
37. Ryan CP, Lee NR, Carba DB, et al. Pregnancy is linked to faster epigenetic aging in young women. *Proc Natl Acad Sci U S A.* 2024;121(16):e2317290121. doi:10.1073/pnas.2317290121
38. Sugden K, Caspi A, Elliott ML, et al. Association of pace of aging measured by blood-based DNA methylation with age-related cognitive impairment and dementia. *Neurology.* 2022;99(13):e1402-e1413. doi:10.1212/WNL.0000000000200898
39. Whitman ET, Ryan CP, Abraham WC, et al. A blood biomarker of the pace of aging is associated with brain structure: replication across three cohorts. *Neurobiol Aging.* 2024;136:23-33. doi:10.1016/j.neurobiolaging.2024.01.008
40. Whitman E, Ryan C, Abraham W, et al. A Blood Biomarker of Accelerated Aging in the Body Associates with Worse Structural Integrity in the Brain: Replication across Three Cohorts.; 2023. doi:10.1101/2023.09.06.23295140
41. Stern Y. Cognitive Reserve. *Neuropsychologia.* 2009;47(10):2015-2028. doi:10.1016/j.neuropsychologia.2009.03.004
42. Raffington L, Belsky DW. Integrating DNA methylation measures of biological aging into social determinants of health research. *Curr Environ Health Rep.* 2022;9(2):196-210. doi:10.1007/s40572-022-00338-8
43. Yaffe K, Vittinghoff E, Dublin S, et al. Effect of personalized risk-reduction strategies on cognition and dementia risk profile among older adults: the SMARTR Randomized Clinical Trial. *JAMA Intern Med.* doi:10.1001/jamainternmed.2023.6279. Published online November 27, 2023.
44. Belsky DW, Caspi A, Cohen HJ, et al. Impact of early personal-history characteristics on the Pace of Aging: implications for clinical trials of therapies to slow aging and extend healthspan. *Aging Cell.* 2017;16(4):644-651. doi:10.1111/accel.12591
45. Belsky DW, Caspi A, Arseneault L, et al. Quantification of the pace of biological aging in humans through a blood test, the DunedinPoAm DNA methylation algorithm. *eLife.* 2020;9. doi:10.7554/eLife.54870
46. Waziry R, Ryan CP, Corcoran DL, et al. Effect of long-term caloric restriction on DNA methylation measures of biological aging in healthy adults from the CALERIE trial. *Nat Aging.* 2023;9:1-10. doi:10.1038/s43587-022-00357-y

## SUPPORTING INFORMATION

Additional supporting information can be found online in the Supporting Information section at the end of this article.

**How to cite this article:** Savin M, Wang H, Pei H, et al. Association of a pace of aging epigenetic clock with rate of cognitive decline in the Framingham Heart Study Offspring Cohort. *Alzheimer's Dement.* 2024;16:e70031. <https://doi.org/10.1002/dad2.70038>